Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®).

@article{Ryan2014ComparativeNA,
  title={Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®).},
  author={Anne M. Ryan and Sharon A. Sokolowski and Chee-Keng Ng and Norimitsu Shirai and Mark Collinge and Amy C. Shen and Joshua Arrington and Zaher Ahmad Radi and Thomas R Cummings and Stephen A. Ploch and Sarah A Stephenson and Niraj K Tripathi and Susan I Hurst and Gregory L. Finch and Michael W. Leach},
  journal={Toxicologic pathology},
  year={2014},
  volume={42 7},
  pages={1069-81}
}
Comparative nonclinical studies were conducted with the proposed biosimilar PF-05280586 and rituximab-EU (MabThera®). In side-by-side analyses, peptide maps and complement-dependent cytotoxicity assay results were similar. Sexually-mature cynomolgus monkeys were administered PF-05280586 or rituximab-EU as a single dose of 0, 2, 10, or 20 mg/kg on day 1 and… CONTINUE READING